We are currently investigating possible Dupixent side effects legal cases for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. These Dupixent side effects legal cases would be filed … More
Main Navigation Menu
➤ Current Drug Injury Lawsuits / Pharmaceutical Litigations
➤ Drug Injury Case Evaluation – Free. Confidential. No Obligation.
➤ Information About the Law Offices of Thomas J. Lamb
➤ Questions New Clients Have Asked Us (FAQs)
➤ Patient Resources: Medical Sites and More
➤ Recent Side Effects Blog Articles
➤ Collection of Earlier Blog Articles
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Case Reports
Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
A 2025 medical study considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to other antidiabetic medications. The researchers concluded that there is an … More
NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound
The possible connection of NAION with tirzepatide-containing drugs Mounjaro and Zepbound is being investigated by the FDA, according to "October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)". During the … More
Link Between Ozempic and NAION Also Involves the Eye Disorder AION
The European Medicines Agency (EMA) confirmed the link between Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator went on to say a NAION warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, Rybelsus, and … More
Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
Patients who have filed Ozempic blindness legal cases had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does … More
Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
The relatively new drug safety issue of vision loss linked to Ozempic and Rybelsus was the subject of a recent medical study that had this stated Objective, or purpose: "To investigate the association between semaglutide use and the risk of NAION among patients with diabetes." On March 27, 2025, … More